



LungLife AI, Inc.
(the "Company" or "LungLife")

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI (AIM: LLA1), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company's website and will be posted to those shareholders who have opted out of electronic communications today.

The documents are available here: lunglifeai.com/investors/financial-information-documents-presentations/

The Company's AGM will be held at 4:00 P.M. (BST) on 5 June 2024, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. The Company will announce details of how to listen to the meeting remotely and any other significant changes to the meeting arrangements via RNS and on LungLife's website at investors.lunglifeai.com/

Shareholders are strongly encouraged to vote by proxy, whether or not you plan to attend the Company's Annual General Meeting in person. You may register your votes on the resolutions of the Annual General Meeting by completing and returning the proxy form that accompanies this Notice in accordance with the instructions printed on the proxy form.

If shareholders' holding of Common Shares is by way of dematerialised depository interests representing underlying Common Shares ("Depository Interests"), they can vote through the CREST system or by returning a Form of Instruction to the Depository. Further instructions are set out in the Notes to the Notice of Annual General Meeting.

The resolutions to be proposed at the Annual General Meeting are summarised in the Notice of AGM.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicably possible after the AGM.

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Joint Broker)
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

Goodbody (Joint Broker)
Tom Nicholson / Cameron Duncan

Tel: +44 (0) 20 3841 6202

Walbrook PR Limited
Stephanie Cuthbert / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAQKQBBABKDDQB